Quarterly ResultJul 30, 2026, 02:20 PM

FMC Q2 Net Loss $186.6M; Restructuring Charges Drive $1.49 EPS Loss

AI Summary

FMC reported a net loss attributable to stockholders of $186.6 million, or $(1.49) per diluted share, for the second quarter of 2026, a significant decline from a net income of $66.7 million, or $0.53 per diluted share, in the prior year. Revenue for the quarter decreased to $867.1 million from $1,050.5 million. The company incurred substantial restructuring and other charges of $222.3 million, primarily due to Project Foundation and an asset impairment related to the India business divestment. FMC also entered a co-exclusive strategic supply and license agreement with Corteva, Inc. for rimisoxafen, receiving a $200 million prepurchase payment.

Key Highlights

Q2 2026 Net Loss attributable to stockholders: $(186.6) million, down from $66.7 million profit in Q2 2025.
Q2 2026 Diluted EPS: $(1.49), compared to $0.53 profit in Q2 2025.
Q2 2026 Revenue: $867.1 million, a decrease from $1,050.5 million in Q2 2025.
Restructuring and other charges totaled $222.3 million in Q2 2026, including $136.5 million for Project Foundation.
Divestment of India commercial business for $252 million, resulting in a $43.6 million asset impairment.
Entered a co-exclusive strategic supply and license agreement with Corteva, Inc. for rimisoxafen, receiving a $200 million prepurchase payment.
Long-term debt increased to $3,954.3 million as of June 30, 2026, from $2,769.8 million at December 31, 2025.
Q2 2026 Revenue by region: North America $248.8 million, Latin America $277.9 million, EMEA $214.1 million, Asia $126.3 million.

View SEC Filing

FMC

Major Chemicals

FMC CORP

Price Impact